Armed with a novel approach for resolving inflammation and expertise ranging from drug discovery through FDA approval, we merge future-focused intention with data-driven innovation. We have earned our reputation by developing Vyleesi® (bremelanotide injection), a novel treatment for women with generalized hypoactive sexual desire disorder (HSDD). We are determined to leverage our unique insight into the industry and the melanocortin system to develop groundbreaking therapeutics for inflammatory and autoimmune diseases, with a focus on ocular conditions.